PF-00258210 + PF-00610355

This drug is a **combination of PF-00258210 and PF-00610355**. PF-00610355 is an orally inhaled, long-acting β₂-adrenoceptor agonist (LABA) developed for once-daily treatment of chronic obstructive pulmonary disease (COPD), with a primary mechanism of producing bronchodilation through selective activation of β₂-adrenergic receptors in airway smooth muscle[1][2][3][5]. It is administered by inhalation and is considered a small molecule. PF-00258210 is another investigational compound developed by Pfizer, but there is insufficient public information on its pharmacology, mechanism, or specific clinical context in this combination. Both compounds are developed by Pfizer.

Other names

PF-610355 (for PF-00610355)